US stock · Healthcare sector · Drug Manufacturers—General

Biogen Inc.

BIIB

NASDAQ

298.66

USD

+1.53

(+0.51%)

Market Closed

12.71P/E

18Forward P/E

0.60P/E to S&P500

43.229BMarket CAP

- -Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

18 Jul-24 Jul

Shares Short

5/15/23

2.96M

Short % of Float

2.31%

Short % of Shares Outs.

2.05%

% Held by Insiders

0.69%

% Held by Institutions

89.90%

Beta

0.19

PEG Ratio

7.70

52w. high/low

319.74/188.54

Avg. Daily Volume

1.02M

Return %

Stock

S&P 500

1 year

29.63

(9.05)

3 years

(11.19)

50.26

5 years

(8.81)

38.50

Scale: |

High

Low

73.59

37.21

55.34

41.75

68.60

45.96

120.66

64.28

157.18

111.44

298.82

139.72

361.93

270.62

480.18

254.00

333.65

223.02

348.84

244.28

388.67

249.17

344.00

215.78

374.99

223.25

468.55

221.72

311.88

187.16

295.90

254.80

Currency: USD

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Revenue per share

10.04

14.02

15.23

18.69

20.83

23.18

29.26

41.05

46.66

52.42

57.73

65.66

76.85

83.56

73.65

68.23

Earnings per share

2.02

2.68

3.38

3.98

5.09

5.80

7.86

12.42

15.37

16.95

11.94

21.62

31.47

24.86

10.44

20.44

FCF per share

2.33

4.41

3.16

5.75

6.09

6.80

(4.91)

11.23

13.32

17.38

12.17

25.87

34.25

22.86

22.43

10.90

Dividends per share

- -

CAPEX per share

0.90

0.94

0.58

0.69

1.04

1.10

14.81

1.22

2.79

3.33

9.23

4.32

3.58

3.43

1.98

(1.61)

Book Value per sh.

17.52

19.86

21.65

21.39

26.51

29.26

36.38

45.73

40.63

55.59

59.33

63.64

71.32

66.50

73.08

89.86

Comm.Shares outs.

316

292

287

252

242

238

237

236

231

218

213

205

187

161

149

Avg. annual P/E ratio

28.3

20.7

14.4

14.1

18.2

23.5

27.6

25.5

22.8

16.6

24.5

14.5

8.4

11.7

27.9

11.3

P/E to S&P500

1.6

1.0

0.2

0.7

1.1

1.6

1.4

1.1

0.7

1.0

0.6

0.3

0.9

0.5

Avg. annual div. yield

- -

Revenue (m)

3,172

4,098

4,377

4,716

5,049

5,516

6,932

9,703

10,764

11,449

12,274

13,453

14,378

13,445

10,982

10,173

Operating margin

24.6%

29.6%

26.5%

34.2%

33.6%

36.3%

40.9%

45.4%

45.0%

43.5%

43.8%

49.0%

33.8%

25.9%

32.0%

Depreciation (m)

380

462

428

354

359

366

532

688

600

683

1,081

1,017

681

457

488

518

Net profit (m)

638

783

970

1,005

1,234

1,380

1,862

2,935

3,547

3,703

2,539

4,431

5,889

4,001

1,556

3,047

Income tax rate

29.9%

31.8%

26.7%

26.9%

26.0%

25.4%

24.2%

25.1%

24.4%

25.1%

47.9%

24.2%

16.3%

19.7%

3.0%

17.6%

Net profit margin

20.1%

19.1%

22.2%

21.3%

24.5%

25.0%

26.9%

30.2%

33.0%

32.3%

20.7%

32.9%

41.0%

29.8%

14.2%

29.9%

Working capital (m)

179

1,535

1,766

1,490

2,063

1,587

1,427

2,453

4,123

5,312

4,505

4,346

3,518

3,145

3,558

6,518

Long-term debt (m)

1,085

1,080

1,066

1,061

687

592

582

6,522

6,513

5,935

5,937

4,872

7,828

6,604

6,614

Equity (m)

5,534

5,806

6,222

5,397

6,425

6,962

8,620

10,809

9,373

12,140

12,613

13,040

13,343

10,700

10,896

13,398

ROIC

10.4%

10.8%

12.8%

14.3%

15.6%

16.6%

18.7%

24.5%

21.5%

20.0%

13.5%

20.9%

27.1%

20.1%

9.3%

14.9%

Return on capital

11.0%

14.2%

16.0%

17.1%

18.9%

18.6%

21.0%

27.6%

24.6%

22.7%

22.2%

23.9%

26.6%

21.2%

7.8%

15.6%

Return on equity

11.5%

13.5%

15.6%

18.6%

19.2%

19.8%

21.6%

27.2%

37.8%

30.5%

20.1%

34.0%

44.1%

37.4%

14.3%

22.7%

Plowback ratio

- -

100.0%

Div.&Repurch./FCF

339.7%

43.5%

77.4%

130.5%

12.4%

60.8%

(34.4)%

33.4%

162.7%

26.4%

52.8%

82.1%

91.6%

181.6%

53.8%

46.2%

Capital Structure

15 Feb · 2023 | Q4

All numbers in millions

Total liabilities

$ 10,222

Total assets

$ 24,554

Long-term debt

$ 6,614

Cash and equiv.

$ 3,419

Goodwill

$ 5,749

Retained earnings

$ 16,959

Common stock

144

Enterprise Value

$ 46,423

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

2,610

3,803

4,893

Receivables

2,327

1,962

1,705

Inventory

1,069

1,352

1,344

Other

881

1,671

3,937

Current assets

6,887

7,857

9,791

Acc. Payable

455

589

492

Debt due

- -

999

- -

Other

3,287

2,710

2,781

Current liabilities

3,742

4,298

3,273

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

(7.36)%

(6.32)%

5.42%

Cash flow

(51.43)%

(20.55)%

(33.11)%

Earnings

95.80%

8.89%

17.94%

Dividends

- -

Book value

22.96%

1.83%

6.25%

Insider Trading

Type

Date

Singhal Priya

Other

341

03/02/23

Singhal Priya

Exempt

297

03/02/23

Singhal Priya

InKind

144

03/02/23

Singhal Priya

Exempt

297

03/02/23

Singhal Priya

InKind

543

03/02/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2020

3,534

3,682

3,376

2,853

13,445

2021

2,694

2,775

2,779

2,734

10,982

2022

2,532

2,589

2,509

2,544

10,173

Earnings per share

Currency: USD

Year

Total

2020

8.70

9.58

4.36

2.22

24.86

2021

2.75

3.01

2.21

2.47

10.44

2022

2.04

7.10

7.61

3.69

20.44

Quarterly dividends paid

Currency: USD

Year

Total

2020

- -

2021

- -

2022

- -

Company Description

Sector:

Healthcare

Industry:

Drug Manufacturers—General

CEO:

Mr. Christopher A. Viehbacher

Full-time employees:

9,610

City:

Cambridge

Address:

225 Binney Street

IPO:

Sep 17, 1991

CIK:

0000875045

Website:

biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Powered by AI

Biogen Inc.

298.66